Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review - Concepedia

Concepedia

Publication | Open Access

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review

DOI Full Paper Access

46

Citations

23

References

2022

Year

Josep M. Llibre, Pedro Cahn, Janet Lo, Tristan Barber, Cristina Mussini, Berend J. van Welzen, Beatríz Hernández, Cynthia Donovan, Michelle Kisare, Myooran Sithamparanathan,

Open Forum Infectious Diseases

Abstract

Results show that dolutegravir plus lamivudine has a comparable impact on inflammatory and atherogenesis biomarkers vs 3/4DRs, with no consistent pattern of change after switch in virologically suppressed PWH.

References

	Year	Citations

Page 1